Nov 19, 2020
Sobi and Apellis announce first patient dosed in potentially registrational ALS study of pegcetacoplan
Nov 06, 2020
Strong Sobi presence at American Society of Hematology 2020 Annual Meeting
Oct 23, 2020
Invitation to the Sobi Capital Markets Day 2020
Oct 22, 2020
Sobi publishes report for the third quarter 2020
Oct 17, 2020
Emapalumab's efficacy confirmed by sensitivity analysis presented at ESID2020
Sep 30, 2020
Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout
Sep 18, 2020
Orfadin® (nitisinone) receives positive opinion from CHMP for treatment of AKU
Sep 10, 2020
New England Journal of Medicine publishes positive final results from phase 1/2a study of BIVV001 in people with severe haemophilia A
Jul 13, 2020
Data Presented at ISTH2020 Strengthens Evidence for Both Elocta® and Alprolix® in Previously Untreated Patients With Haemophilia
Jul 06, 2020
Invitation - Presentation of Sobi's Q2 2020 Results
Jun 26, 2020
Successful Elocta Bid Means Increased Access for People With Haemophilia A in the UK
Jun 14, 2020
Sobi and Sanofi Donate up to 500 Million Additional IUs of Clotting Factor to WFH Humanitarian Aid Program
Jun 11, 2020
Sobi and Selecta Announce Strategic Licensing Agreement for SEL-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout
Apr 22, 2020
Sobi(TM) Affiliate Florio GmbH, Launches a New Digital Platform Aiming to Improve the Lives of People with Haemophilia
Apr 22, 2020
Invitation - Presentation of Sobi's Q1 2020 Results
Apr 20, 2020
Sobi Offers Advance Voting at the 2020 Annual General Meeting
Apr 17, 2020
New Data Shows Varied State of Haemophilia Treatment Around the World: Sobi
Apr 13, 2020
Sobi Sees Strong Revenue and EBITA Growth in the First Quarter 2020
Apr 07, 2020
Sobi(TM) Publishes 2019 Annual and Sustainability Report
Feb 28, 2020
New Research Uncovers the Toll Rare Diseases Take on Relationships